14,114 Shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC) Purchased by Paloma Partners Management Co

Paloma Partners Management Co bought a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 14,114 shares of the company’s stock, valued at approximately $1,325,000.

Other large investors have also recently made changes to their positions in the company. Bellevue Group AG grew its stake in shares of GE HealthCare Technologies by 2.1% in the third quarter. Bellevue Group AG now owns 531,967 shares of the company’s stock worth $49,925,000 after acquiring an additional 10,950 shares during the last quarter. Verition Fund Management LLC increased its stake in GE HealthCare Technologies by 15.4% during the 3rd quarter. Verition Fund Management LLC now owns 15,798 shares of the company’s stock valued at $1,483,000 after purchasing an additional 2,113 shares in the last quarter. Captrust Financial Advisors raised its holdings in GE HealthCare Technologies by 1.6% in the third quarter. Captrust Financial Advisors now owns 33,353 shares of the company’s stock worth $3,130,000 after buying an additional 534 shares during the last quarter. William Allan Corp raised its holdings in GE HealthCare Technologies by 7.6% in the third quarter. William Allan Corp now owns 23,979 shares of the company’s stock worth $2,250,000 after buying an additional 1,687 shares during the last quarter. Finally, D1 Capital Partners L.P. bought a new position in shares of GE HealthCare Technologies in the third quarter worth approximately $268,159,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies Trading Down 0.2 %

Shares of GE HealthCare Technologies stock opened at $83.08 on Tuesday. GE HealthCare Technologies Inc. has a 1-year low of $67.00 and a 1-year high of $94.55. The company’s fifty day simple moving average is $87.78 and its 200-day simple moving average is $83.65. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The stock has a market capitalization of $37.96 billion, a PE ratio of 22.82, a P/E/G ratio of 2.98 and a beta of 1.24.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The business had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. During the same quarter in the previous year, the company posted $0.99 earnings per share. GE HealthCare Technologies’s revenue for the quarter was up .9% on a year-over-year basis. As a group, equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be issued a $0.035 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. GE HealthCare Technologies’s payout ratio is currently 3.85%.

Insiders Place Their Bets

In other news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. Wells Fargo & Company boosted their price target on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. began coverage on GE HealthCare Technologies in a research report on Monday, September 9th. They set a “neutral” rating and a $90.00 price objective on the stock. Evercore ISI boosted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, BTIG Research raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, GE HealthCare Technologies has an average rating of “Moderate Buy” and an average target price of $95.46.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.